跳至主要内容
临床试验/NCT05802381
NCT05802381尚未招募不适用

the Safety and Effectiveness of Protein Supplements on Cancer Patients With Nutritional Risk and Malnutrition

Peking Union Medical College Hospital0 个研究点目标入组 100 人开始时间: 2023年4月最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
100
主要终点
nutritional risk

研究概览

简要总结

Nutritional risk and malnutrition is common in cancer patients, which is one of the significant factors affecting the overall survival, toxicity during anticancer treatment, and quality of life among patients with cancer. Previous studies have shown that the increased protein intake can stimulate muscle synthesis, and improve muscle mass, strength, function, overall survival, and quality of life. The current study is going to investigate the effectiveness and safety of protein supplements on patients with cancer, in order to provide a reference for further nutrition treatment.

详细描述

An anticipated total of 100 participants will randomly assigned to receive either a 20-gram protein supplement per day or nutrition counseling to increase the protein intake. there will be a total of 3 study visits, and dietary assessment and blood sample collection will occur at every study visit. Intention-to-treat analysis (ITT) and per-protocol analysis (PP) will be used in statistical analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • • Age>=18years old;
  • Initial treatment patients with lung/gastrointestinal/esophageal cancer
  • Patients with nutritional risk (NRS-2002≥3) ;
  • Patients are able to provide written informed consent.

排除标准

  • • People who are allergic to whey protein.
  • Participants received any drugs or supplements known to influence the outcomes, such as protein powder, anabolic steroids, or glucocorticoids before the 3 months preceding the study.
  • Participants with gastrointestinal bleeding or intestinal obstruction, or any contraindication for oral intake
  • Concurrent severe cardiac disease, liver and renal failure, which may significantly interfere with study compliance.
  • Participants with electronic or mental device.
  • Women in pregnancy or lactation period

结局指标

主要结局

nutritional risk

时间窗: 6 months

nutritional risk based on nutrition risk screening-2002 (NRS-2002)

malnutrition

时间窗: 6 months

malnutrition assessment based on Global Leadership Initiative on Malnutrition (GLIM)

blood toxicity

时间窗: 6 month

blood toxicity based on Common Terminology Criteria for Adverse Events (CTCAE)

次要结局

  • phase angle (PA)(6 month)
  • dose limitation(6 months)
  • weight(6 month)

研究者

申办方类型
Other
责任方
Sponsor

相似试验